AstraZeneca said on Friday that its and Daiichi Sankyo’s cancer drug Enhertu has been recommended by the European Medicines Agency’s human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC).
The recommendation is based on mid-stage data where Enhertu showed a confirmed objective response rate of 49% and a median duration of response of 16.8 months in patients previously treated for lung cancer.
EU ASSESSES HUMAN AND LABOR RIGHTS IN BURMA
AstraZeneca’s cancer drug Enhertu, a drug jointly developed with Japan’s Daiichi Sankyo, is pictured in an undated brochure image obtained by Reuters on June 27, 2022. (AstraZeneca/Handout via REUTERS/File photo)
CLICK HERE TO GET THE FOX NEWS APP
The drug is already approved in the European Union as a treatment for patients with advanced breast cancer.
The recommendations of the Committee for Medicinal Products for Human Use should be formally approved by the European Commission.
